Home > > Global Fibromyalgia Treatment Market Report
The Fibromyalgia Treatment market was valued at $2,512.7 Million in 2024, and is projected to reach $4,427.3 Million by 2031 growing at a CAGR of 8.49% from 2025 to 2031. Antiepileptic segment is expected to be the highest contributor to this market, with $1,553.0 Million in 2024, and is anticipated to reach $2,643.9 Million by 2031, registering a CAGR of 7.96%. Muscle Relaxants segment is anticipated to reach $916.1 Million by 2031 with the highest CAGR of 9.78%. Antiepileptic and Muscle Relaxants segments collectively expected to account for about 80.8% share of the Fibromyalgia Treatment market in 2024, with the former constituting around 61.8% share. Muscle Relaxants and Antidepressants segments are expected to witness significant growth rates at a CAGR of 9.78% and 9.35% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 31.9% in the overall Fibromyalgia Treatment market in 2024, and is anticipated to reach 34.3% by 2031.